Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of oligomeric guluronic acid salts in preparation of Parkinson's disease prevention and treatment drugs or products

A technology of guluronic acid salt and polyguluronic acid, applied in the field of marine medicine, can solve problems such as anti-Parkinson's disease that have not yet been seen, and achieve broad development and application prospects, abundant resources, and easy industrialization. Effect

Active Publication Date: 2014-07-30
MARINE BIOMEDICAL RES INST OF QINGDAO CO LTD
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, domestic and foreign literatures have reported that oligoglucuronic acid has various biological activities such as anti-oxidation, immune regulation, and regulation of mucosal protein functions, but there is no research on its application in protecting mitochondrial damage and resisting Parkinson's disease. to report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of oligomeric guluronic acid salts in preparation of Parkinson's disease prevention and treatment drugs or products
  • Application of oligomeric guluronic acid salts in preparation of Parkinson's disease prevention and treatment drugs or products
  • Application of oligomeric guluronic acid salts in preparation of Parkinson's disease prevention and treatment drugs or products

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1: Preparation of oligomeric guluronic acid salt (LPG)

[0025] Prepare alginate (sodium alginate in this example) into a 10wt% aqueous solution, heat it to 80-90°C with 1wt% dilute hydrochloric acid, stir and degrade it for 4-5 hours, neutralize it with 10wt% sodium carbonate aqueous solution after cooling, and then Use 5wt% dilute hydrochloric acid to adjust the pH to about 3.65, centrifuge to collect the precipitate, dissolve it with 2mol / L NaOH, add 3 times the volume of 95wt% ethanol, collect the precipitate, dehydrate with absolute ethanol and dry to obtain polyguluronic acid sodium salt (Mw=11.2kD). The polyguluronic acid sodium salt was formulated with pure water into 10wt% aqueous solutions of different concentrations, and degraded by the Fenton method to obtain oligomeric guluronic acids with different molecular weights. After the oligomeric guluronic acid is neutralized by lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide...

Embodiment 2

[0030] Embodiment 2: the present invention adopts MPP + Inducing SK-N-MC neuroblasts to establish a Parkinson's disease model. The model has clinical and pathological features similar to Parkinson's disease: the activity of mitochondrial complex I is significantly reduced, ATP energy deficiency, and mitochondrial dysfunction.

[0031] The present embodiment adopts the oligomeric guluronic acid sodium salt obtained in Example 1. When SK-N-MC cells adhered to the wall at about 80%, they were digested and passaged with 0.25wt% trypsin. SK-N-MC cells that grew well and were in the logarithmic phase were made into cell suspension, and then press 5×10 4 / mL seeded in 96-well cell culture plate, at 37°C, 5% CO 2 Cultivate in the cell incubator for 24 hours, suck away the old medium, and set up the blank control group, model group, positive control group (LA), and sample protection group (LPG) respectively. The LA concentration of the positive control group is 50 μM, and the sample...

Embodiment 3

[0038] The present embodiment adopts the oligomeric guluronic acid sodium salt obtained in Example 1. SK-N-MC cells that grew well and were in the logarithmic phase were made into cell suspension, and then press 5×10 4 / mL seeded in 96-well cell culture plate, at 37°C, 5% CO 2 Cultivate in the cell incubator for 24 hours, suck away the old medium, and set up the blank control group, model group, positive control group (LA), and sample protection group (LPG) respectively. The LA concentration of the positive control group is 50 μM, and the sample protection group Add 200 μL of fresh medium containing samples to make the final concentration of the drug 50 μM, respectively add medium containing equal volumes of ultrapure water to the blank control group and model group, and continue to cultivate for 24 hours. The cells were washed once with PBS, and the intracellular ROS level was detected with DCFH-DA fluorescent probe. DCFH-DA itself is a non-fluorescent substance. After ente...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of marine drugs, and concretely relates to an application of oligomeric guluronic acid salts in the preparation of Parkinson's disease prevention and treatment drugs or products. The oligomeric guluronic acid salts can be used for preparing Parkinson's disease prevention and treatment drugs or products, and are obtained through a step of carrying out a chemical degradation process or a physical degradation process on algin as a raw material to obtain oligomeric guluronic acid with different molecular weights, and neutralizing the oligomeric guluronic acid with different molecular weights to prepare lithium salt, sodium salt, calcium salt or magnesium salt of oligomeric guluronic acid with different molecular weights, wherein the molecular skeleton is a linear oligosaccharide compound formed by bonding L-guluronic acid (G) through an alpha-(1,4)-glycosidic bond. Experiments in the invention prove that the application of the oligomeric guluronic acid salts in Parkinson's disease prevention and treatment or improvement for the first time; and test results show that the oligomeric guluronic acid salts have no side toxic effects on nerve cells, is suitable for long term use, and has a wide market application prospect in the Parkinson's disease prevention and treatment.

Description

technical field [0001] The invention belongs to the field of marine drugs, and in particular relates to the application of an oligomeric guluronic acid salt in the preparation of drugs or products for preventing and treating Parkinson's disease (Parkin). Background technique [0002] With the improvement of the quality of life of modern people, the aggravation of the aging of human society, and the change of environmental factors, the prevalence of Parkinson's is showing an upward trend year by year, which has caused serious mental and economic burdens to patients, family members, and society. The main pathological features of Parkinson's disease are chronic degeneration and necrosis of dopaminergic neurons in the substantia nigra, and the formation of Lewy bodies in the cytoplasm. At present, the clinical drugs used to treat Parkinson's disease are roughly divided into two categories: anticholinergic drugs and dopaminergic drugs. Most of these drugs can only delay the progr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/702A61K31/734A61P25/16A23L1/30
Inventor 管华诗郝杰杰胡婷敦云楼周晓琳夏萱
Owner MARINE BIOMEDICAL RES INST OF QINGDAO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com